Kaposi's sarcoma after liver transplantation

Dermatology. 1996;193(2):100-4. doi: 10.1159/000246221.

Abstract

Background: Kaposi's sarcoma (KS), is a known complication following kidney transplantation. It has been reported more rarely following liver transplantation.

Objective: To assess the clinico-epidemiologic data of KS after liver transplantation.

Methods: 150 liver graft recipients were examined; those presenting with KS were studied clinically, histologically and virologically.

Results: Three cases of KS were observed. The three patients had been treated with OKT3 antiserum in addition to the standard regimen. The delay of appearance varied from 5 to 36 months. Two patients had a few cutaneous lesions and 1 had more extensive involvement; none of them had visceral localizations. In 2 cases, herpesvirus-like DNA sequences were detected within the lesions. Therapy consisted in decreasing the immunosuppressive treatment, in association with alpha-interferon or vindesine in 2 cases, respectively. All patients were alive after a follow-up of 19-45 months.

Conclusion: KS seems relatively frequent (2%) and appears within a short delay after liver transplantation; the prognosis may be more favourable than previously reported.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Antineoplastic Agents / therapeutic use
  • Antineoplastic Agents, Phytogenic / therapeutic use
  • Base Sequence
  • DNA, Viral / analysis
  • Female
  • Follow-Up Studies
  • Herpesviridae / genetics
  • Humans
  • Immunosuppressive Agents / administration & dosage
  • Immunosuppressive Agents / therapeutic use
  • Interferon-alpha / therapeutic use
  • Liver Transplantation* / adverse effects
  • Male
  • Middle Aged
  • Muromonab-CD3 / administration & dosage
  • Muromonab-CD3 / therapeutic use
  • Prognosis
  • Sarcoma, Kaposi / drug therapy
  • Sarcoma, Kaposi / etiology*
  • Sarcoma, Kaposi / pathology
  • Sarcoma, Kaposi / virology
  • Skin Neoplasms / drug therapy
  • Skin Neoplasms / etiology*
  • Skin Neoplasms / pathology
  • Skin Neoplasms / virology
  • Survival Rate
  • Vindesine / therapeutic use

Substances

  • Antineoplastic Agents
  • Antineoplastic Agents, Phytogenic
  • DNA, Viral
  • Immunosuppressive Agents
  • Interferon-alpha
  • Muromonab-CD3
  • Vindesine